Detailed Information
Cited 62 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
- Authors
- Cohen, YC[Cohen, Yael C.]; Morillo, D[Morillo, Daniel]; Gatt, ME[Gatt, Moshe E.]; Sebag, M[Sebag, Michael]; Kim, K[Kim, Kihyun]; Min, CK[Min, Chang-Ki]; Oriol, A[Oriol, Albert]; Ocio, EM[Ocio, Enrique M.]; Yoon, SS[Yoon, Sung-Soo]; Mateos, MV[Mateos, Maria-Victoria]; Chu, M[Chu, Michael]; Rodriguez-Otero, P[Rodriguez-Otero, Paula]; Avivi, I[Avivi, Irit]; Guo, Y[Guo, Yue]; Krevvata, M[Krevvata, Maria]; Peterson, MR[Peterson, Michelle R.]; Beelen, MJ[Beelen, Melissa Jo]; Vanak, J[Vanak, Jill]; Banerjee, A[Banerjee, Arnob]; Magen, H[Magen, Hila]
- Issue Date
- 1-Jun-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.